Sensus Healthcare, Inc. - Common Stock (SRTS)

Three systems on rental or Fair Deal terms shifted how revenue was recognized.

Sensus Healthcare (NASDAQ:SRTS) reported lower third-quarter revenue despite shipping more superficial radiation therapy systems, as product mix and the absence of sales to its historically largest customer weighed on the top line. Revenue fell 13% to $6 million from $6.9 million a year earlier, wh

Financing delays crushed Q2 revenue, but management expects recovery in Q3.

Sensus Healthcare (NASDAQ:SRTS) reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June. Chairman and Chief Executive Officer Joe Sard

Sensus Healthcare (NASDAQ:SRTS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive

Sensus Healthcare (NASDAQ:SRTS) said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer. Chairman and Chief Exec

Sensus (SRTS) Q1 2026 Earnings Transcript

Sensus Healthcare SRTS Q4 2025 Earnings Transcript

Sensus SRTS Q3 2025 Earnings Call Transcript

Sensus Healthcare (SRTS) beat Q3 2025 earnings estimates despite a revenue dip. The company highlighted a key regulatory win with new CPT codes for its skin cancer treatment technology.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.